Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

How Much Crude Oil Do You Unknowingly Eat?

You may think (or hope) that in your daily life you don't need to worry about unknowingly eating or otherwise ingesting crude oil or any of its many, many petrochemical byproducts. But you would be wrong. And not just a little wrong--very, very wrong. Petroleum-based substance...
Haley Zaremba | December 5, 2019 |

XPhyto: Is Mescaline the Next Big Mood-Modifying Medicine?

It has the potential to be the next frontier in the psychedelics renaissance, and it represents an unprecedented opportunity to innovate a notable advancement in mental health therapy. In anecdotal studies, mescaline has shown promise in treating depression, anxiety, PTSD,...
Marc Davis | April 6, 2021 |

Assertio Therapeutics' Shares Jump 50% on Sale of Shingles Pain Drug to Alvogen

Assertio Therapeutics' shares rose 50% today after the firm reported that it has agreed to sell all rights to its Gralise drug used in the treatment of pain from shingles to Alvogen for $127.5 million. The transaction is expected to close in January 2020. Shares of ph...
Streetwise Reports | December 13, 2019 |

High Returns

Download the report today!
| April 4, 2023 |

Thematica Report: Exploring the opportunities in alternative healthcare

An investor’s guide to opportunities in the alternative healthcare market. Click here to access the report.On a broad scale, the complementary and alternative medicine (CAM) market...
Jocelyn Aspa | July 13, 2022 |

How to Buy Penny Stocks

A "penny stock" (also known as a micro-cap stock) is a publicly-traded stock with an extremely low price per share – usually under five dollars and often less than a dollar (hence the name "penny" stock). They are typically issued by small, less-established companies. Be ...
Stockhouse Editorial | July 24, 2019 |

Precision Medicine Firm Announces 'Positive' Data in Lymphoma Study

The highlights of the results were presented in an H.C. Wainwright & Co. report. In a June 14 research note, H.C. Wainwright & Co. analyst Joseph Pantginis reported that Kura Oncology Inc. (KURA:NASDAQ) met the endpoint in its Phase 2 clinical trial of...
Streetwise Reports | June 21, 2019 |

Novamind’s Trial Site for Merck Another Example Of Its Leadership in Mental Health

Novamind’s clinics and clinical research capabilities are already well established to bring alternative mental health therapies, including psychedelic medicine, to market. One of the world’s largest pharmaceutical companies has selected ...
Featured Submission | March 24, 2021 |

Fiscal Year 'Reads Well' for Regenerative Medicine Company

The firm's final quarter and full-year results are reviewed in a Ladenburg Thalmann report. In an Aug. 30 research note, Ladenburg Thalmann analyst Jeffrey Cohen reported Mesoblast Ltd.'s (MESO:NASDAQ; MSB:ASX) financial results for Q4/19 and fiscal year 2019 (FY19)...
Streetwise Reports | September 5, 2019 |

Novamind Selected by Merck to Advance Research for Treatment-Resistant Depression

Novamind’s subsidiary, Cedar Clinical Research, to serve as a key clinical research site Independent validation of the expertise and capabilities of Novamind in managing clinical trials Adds to established track record conducting research a...
Featured Submission | March 18, 2021 |
1 2 3 4 5 6 7 8 9 10 ...